Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.

[1]  L. Kèlland,et al.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. , 1995, British Journal of Cancer.

[2]  L. Kèlland,et al.  Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. , 1994, British Journal of Cancer.

[3]  S. Fosså,et al.  Interferon-α, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study , 1994 .

[4]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Kèlland,et al.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. , 1993, British Journal of Cancer.

[6]  I. Judson,et al.  The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. , 1993, Biochemical pharmacology.

[7]  L. Specht,et al.  Radiotherapy versus combined modality in early stages. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. O'Neill,et al.  Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. , 1992, Cancer research.

[9]  N. Saijo,et al.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line. , 1992, British Journal of Cancer.

[10]  B. Hill,et al.  Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. , 1992, Cancer research.

[11]  L. Kèlland,et al.  Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. , 1992, Cancer research.

[12]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[13]  R. Ozols.  Ovarian cancer: new clinical approaches. , 1991, Cancer treatment reviews.

[14]  B. Teicher,et al.  Characteristics of five human tumor cell lines and sublines resistant to cis‐diamminedichloroplatinum(II) , 1991, International journal of cancer.

[15]  N. Saijo,et al.  Collateral sensitivity of cisplatin-resistant human lung cancer cell lines to thymidylate synthase inhibitors , 1990 .

[16]  R. Moran,et al.  Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. , 1990, Cancer research.

[17]  M. Kashani-Sabet,et al.  Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. , 1989, Anticancer research.

[18]  L. Kèlland,et al.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.

[19]  M. Kashani-Sabet,et al.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Lu,et al.  Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. , 1988, Biochemical pharmacology.

[21]  B. Teicher,et al.  Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[22]  R C Young,et al.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.

[23]  B. Woda,et al.  Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. , 1990, Cancer research.

[24]  M. Kashani-Sabet,et al.  Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. , 1989, Cancer communications.

[25]  I. Judson,et al.  Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717). , 1987, NCI monographs : a publication of the National Cancer Institute.

[26]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[27]  C. Heidelberger,et al.  Fluorinated pyrimidines and their nucleosides. , 1983, Advances in enzymology and related areas of molecular biology.